Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study

Vermeulen, R F M; Beurden, Marc van; Kieffer, Jacobien M.; Bleiker, Eveline M. A.; Valdimarsdottir, Heiðdís; Massuger, Leon F.A.G.; Mourits, Marian J.E.; Gaarenstroom, Katja N.; Dorst, E.B.L. van; Putten, H.W.H.M. van der; Aaronson, Neil K.

doi:10.1016/j.ejca.2017.07.018

Cited by 42 publications

(28 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This has a negative impact on patient quality of life, function, and recovery back to baseline. Data from a recent prospective multicenter observational study showed that women who start hormone replacement therapy (HRT) immediately after risk-reducing salpingo-oophorectomy may experience a smaller burden of endocrine symptoms than women who delay HRT initiation [161]. These and similar data indicate that estrogen therapy is most beneficial when started at the time of oophorectomy and continued at least until age 50 years [160].…”

Section: Hormonal Contraceptives and Hormone Replacement Therapymentioning

confidence: 95%

Enhanced Recovery and Surgical Optimization Protocol for Minimally Invasive Gynecologic Surgery: An AAGL White Paper

Stone¹,

Carey

Fader³

et al. 2021

Journal of Minimally Invasive Gynecology

View full text Add to dashboard Cite

This is the first Enhanced Recovery After Surgery (ERAS) guideline dedicated to standardizing and optimizing perioperative care for women undergoing minimally invasive gynecologic surgery. The guideline was rigorously formulated by an American Association of Gynecologic Laparoscopists Task Force of US and Canadian gynecologic surgeons with special interest and experience in adapting ERAS practices for patients requiring minimally invasive gynecologic surgery. It builds on the 2016 ERAS Society recommendations for perioperative care in gynecologic/oncologic surgery by serving as a more comprehensive reference for minimally invasive endoscopic and vaginal surgery for both benign and malignant gynecologic conditions. For example, the section on preoperative optimization provides more specific recommendations derived from the ambulatory surgery and anesthesia literature for the management of anemia, hyperglycemia, and obstructive sleep apnea. Recommendations pertaining to multimodal analgesia account for the recent Food and Drug Administration warnings about respiratory depression from gabapentinoids. The guideline focuses on workflows important to high-value care in minimally invasive surgery, such as same-day discharge, and tackles controversial issues in minimally invasive surgery, such as thromboprophylaxis. In these ways, the guideline supports the American Association of Gynecologic Laparoscopists and our collective mission to elevate the quality and safety of healthcare for women through excellence in clinical practice.

show abstract

Section: Hormonal Contraceptives and Hormone Replacement Therapymentioning

confidence: 95%

Enhanced Recovery and Surgical Optimization Protocol for Minimally Invasive Gynecologic Surgery: An AAGL White Paper

Stone¹,

Carey

Fader³

et al. 2021

Journal of Minimally Invasive Gynecology

View full text Add to dashboard Cite

show abstract

“…The Functional Assessment of Cancer-Therapy-Endocrine Symptoms (FACT-ES) was used to assess endocrine symptoms commonly experienced by women after natural, surgically-induced, or medically-induced menopause. The FACT-ES was used in this population before [23,24] and a validation study showed that the FACT-ES has acceptable validity reliability and is sensitive to clinically significant change [25]. The FACT-ES consists of 18 items that address a range of menopausal symptoms.…”

Section: Methodsmentioning

confidence: 99%

Does anti-Müllerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy? A prospective observational study

et al. 2018

Self Cite

View full text Add to dashboard Cite

Does anti-Müllerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy? A prospective observational study Objectives The aim of this study was to investigate whether serum Anti Müllerian hormone (AMH) predict symptom burden after risk-reducing salpingo-oophorectomy (RRSO) in order to individualize counselling. Methods Patient-reported menopausal symptoms, sexual functioning and psychological distress (depression and anxiety) were assessed one day before (T0), and six weeks (T1) and seven months (T2) after RRSO. AMH was assessed before RRSO. Multivariable regression analysis was used to investigate the association between AMH and short-term and long-term change in symptom burden following RRSO. Results 91 premenopausal women at high risk of ovarian cancer were included. Pre-surgical AMH was not related significantly to change in symptoms post-RRSO. As secondary outcome we found that regular menses before RRSO was associated specifically with long-term increase in hot flushes (sr 0.40, p=0.001; total R 2 0.171) and depression (sr 0.29 p=0.012; total R 2 0.132). Earlier receipt of chemotherapy was associated with long-term improvement in sexual functioning (sr 0.24, p=0.041; total R 2 0.348). Conclusions In this cohort, AMH was not a significant predictor of change in symptoms following RRSO. Regular menses prior to RRSO and earlier receipt of chemotherapy were significantly, but relatively weakly associated with changes in outcomes six weeks and/or seven months after RRSO.

show abstract

“…86,87 The latter has been disputed in a more recent prospective study, which found that women using HT following riskreducing bilateral salpingo-oophorectomy report approximately the same levels of endocrine symptoms and sexual functioning as women in the screening group. 88 While in women with Lynch syndrome, the risk-reducing surgery includes hysterectomy in view of their endometrial cancer risk, in BRCA mutation carriers the current consensus is not to undertake hysterectomy. A multicenter prospective cohort study has shown a small increase in risk of serous or serous-like endometrial carcinoma in BRCA1 mutation carriers.…”

Section: Risk-reducing Bilateral Salpingo-oophorectomymentioning

confidence: 99%

Ovarian Cancer Prevention and Screening

Menon

Karpinskyj

Gentry‐Maharaj

2018

Obstetrics &Amp; Gynecology

207

142

View full text Add to dashboard Cite

There has been much progress in ovarian cancer screening and prevention in recent years. Improved tools that combine genetic and epidemiologic factors to predict an individual's ovarian cancer risk are set to become available for tailoring preventive and screening approaches. The increasing evidence on tubal origins of a proportion of ovarian cancer has paved the way to use of opportunistic bilateral salpingectomy at tubal ligation and hysterectomy in the general population. Clinical trials are in progress to estimate the long-term effects on endocrine function. In women at high risk, risk reducing salpingo-oophorectomy remains the standard of care with the current focus on management of resulting noncancer outcomes, especially sexual dysfunction in younger women. This has led to evaluation of early bilateral salpingectomy and delayed oophorectomy in this population. Meanwhile, modeling suggests that BRCA mutation carriers should consider using the oral contraceptive pill for chemoprevention. In the general population, the largest ovarian cancer screening trial to date, the UK Collaborative Trial of Ovarian Cancer Screening reported a stage shift with annual multimodal screening using the longitudinal CA 125 Risk of Ovarian Cancer Algorithm but not with annual transvaginal ultrasound screening. There was no definitive mortality reduction with either screening strategy compared with no screening. Further follow-up until December 2018 in now underway. Stage shift and higher rates of optimal cytoreduction were also reported during 3- to 4-monthly multimodal screening in the United Kingdom and U.S. high-risk screening trials. Although all agree that there is not yet evidence to support general population screening, recommendations for high-risk screening vary between countries. A key finding from the screening trials has been the better performance of longitudinal algorithms compared with a single cutoff for CA 125. A major focus of ovarian cancer biomarker discovery work has been tumor DNA markers in both plasma and novel specimens such as cervical cytology samples.

show abstract

Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study

Cited by 42 publications

References 38 publications

Enhanced Recovery and Surgical Optimization Protocol for Minimally Invasive Gynecologic Surgery: An AAGL White Paper

Enhanced Recovery and Surgical Optimization Protocol for Minimally Invasive Gynecologic Surgery: An AAGL White Paper

Does anti-Müllerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy? A prospective observational study

Ovarian Cancer Prevention and Screening

Contact Info

Product

Resources

About